AXSM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXSM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.
Axsome Therapeutics's Cash from Discontinued Operating Activities for the three months ended in Mar. 2024 was $0.0 Mil. It means Axsome Therapeutics received $0.0 Mil from discontinued investing activities. Axsome Therapeutics's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Mar. 2024 was $0.0 Mil.
The historical data trend for Axsome Therapeutics's Cash from Discontinued Operating Activities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash from Discontinued Operating Activities | Get a 7-Day Free Trial | - | - | - | - | - |
Axsome Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash from Discontinued Operating Activities | Get a 7-Day Free Trial | - | - | - | - | - |
Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.
Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Axsome Therapeutics's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.
Susan Mahony | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Mark Coleman | director | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Hunter R. Murdock | officer: General Counsel | 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007 |
Roger Jeffs | director | |
Nick Pizzie | officer: Chief Financial Officer | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Mark E Saad | director | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Herriot Tabuteau | director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER | |
Mark L. Jacobson | officer: Chief Operating Officer | 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038 |
David C Marek | officer: Chief Commercial Officer | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
John Golubieski | officer: Chief Financial Officer | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862 |
Myrtle S Potter | director | 10 FINDERNE AVE, BRIDGEWATER NJ 08807 |
Randall Kaye | officer: Chief Medical Officer | 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121 |
Ames Constance | officer: Vice President, Finance | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Antecip Capital Llc | 10 percent owner | 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111 |
From GuruFocus
By GlobeNewswire • 06-28-2023
By PRNewswire • 11-20-2023
By Business Wire • 09-29-2023
By sperokesalga sperokesalga • 03-01-2023
By Marketwired • 07-07-2023
By sperokesalga sperokesalga • 05-30-2023
By Marketwired • 10-02-2023
By sperokesalga sperokesalga • 05-01-2023
By sperokesalga sperokesalga • 04-21-2023
By GuruFocus Research • 11-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.